Please login to the form below

Not currently logged in
Email:
Password:

Alacrita appoints Stuart Hendry as associate partner

Joins from medical device firm Sphere Medical

edit-StuartHendryLife sciences management consultancy firm Alacrita has appointed Stuart Hendry as an associate partner.

He will be based in the Cambridge, UK, office and will help serve Alacrita's growing roster of clients in the medical device and diagnostics sectors.

Hendry said: “I am very pleased to join the excellent team at Alacrita and I look forward to contributing to the firm's medtech activities in this extremely exciting time for life sciences and medical devices globally.”

Hendry has over 25 years of experience in the industry and joins the company from Sphere Medical, a UK medical device company, where he worked as CEO.

Prior to Sphere Medical, he held a number of senior operational roles, including at Pfizer Hospital Products, Diametrics and PowderJect and he has also worked as head of life sciences at Scientific Generics.

Mark Wickham, Alacrita partner and head of their medtech practice, added: “We believe that seasoned industry expertise is essential to deliver value to a sophisticated life science client.

“With the addition of Stuart to the partnership, we are better positioned than ever to serve our innovative medtech client who are focussed on bringing complex, differentiated medical solutions to the world's patient populations.”

30th September 2014

From: Marketing

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Pharma M&A
Pharma funding and M&A in 2020
Why pharma M&A has continually bucked the trend...

Infographics